Hamilton-Miller J M, Shah S
Department of Medical Microbiology, Royal Free Hospital School of Medicine, London, UK.
J Antimicrob Chemother. 1997 May;39(5):575-84. doi: 10.1093/jac/39.5.575.
The in-vitro antibacterial activity of Men 10700, a novel penem, has been compared with that of ritipenem, ciprofloxacin, amikacin, cefotaxime and co-amoxiclav against 539 strains taken from 17 genera. Men 10700 was most active against staphylococci and streptococci (MIC90 < 0.5 mg/L), slightly less active against Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Citrobacter spp., Moraxella catarrhalis and peptostreptococci (MIC90 0.5-2 mg/L), moderately active against Enterococcus faecalis, members of the tribe Proteae, Serratia marcescens, Acinetobacter spp., clostridia and Bacteroides spp. (MIC90 4-16 mg/L), and inactive against Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Enterococcus faecium. Its antibacterial spectrum is thus slightly less broad than that of imipenem, but it compares favourably with an oral third-generation cephalosporin. Men 10700 was more active than ritipenem against many species, especially Enterobacter spp. and Citrobacter spp.
新型青霉烯类药物美罗培南（Men 10700）的体外抗菌活性已与利替培南、环丙沙星、阿米卡星、头孢噻肟和阿莫西林克拉维酸针对来自17个菌属的539株菌株的抗菌活性进行了比较。美罗培南对葡萄球菌和链球菌活性最强（MIC90<0.5mg/L），对大肠杆菌、肺炎克雷伯菌、肠杆菌属、柠檬酸杆菌属、卡他莫拉菌和消化链球菌活性稍弱（MIC90 0.5-2mg/L），对粪肠球菌、变形菌族成员、粘质沙雷菌、不动杆菌属、梭菌属和拟杆菌属中度敏感（MIC90 4-16mg/L），对铜绿假单胞菌、嗜麦芽窄食单胞菌和屎肠球菌无活性。因此，其抗菌谱比亚胺培南略窄，但与口服第三代头孢菌素相比具有优势。美罗培南对许多菌种的活性比利替培南更强，尤其是肠杆菌属和柠檬酸杆菌属。
